Viewing Study NCT06456970



Ignite Creation Date: 2024-06-16 @ 11:52 AM
Last Modification Date: 2024-10-26 @ 3:32 PM
Study NCT ID: NCT06456970
Status: NOT_YET_RECRUITING
Last Update Posted: 2024-06-13
First Post: 2024-06-09

Brief Title: Frequency of Metabolic Dysfunction Associated Fatty Liver Disease in Patients With Acute Coronary Syndromes
Sponsor: Assiut University
Organization: Assiut University

Study Overview

Official Title: Frequency of Metabolic Dysfunction Associated Fatty Liver Disease in Patients With Acute Coronary Syndromes
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Aim of the research is to assess frequency of MAFLD among patients with acute coronary syndromes ACS
Detailed Description: Hepatic manifestation of metabolic syndrome MS is known as Metabolic Dysfunction Associated Fatty Liver Disease MAFLD MAFLD could be complicated by serious events as steatohepatitis cirrhosis and malignant liver The characteristics histological findings in those patients are macrovesicular steatosis The prevalence of MAFLD has doubled over the last 20 years

Globally based on many reported studies its well-known that in 25-28 of deaths in patients with Metabolic Dysfunction Associated Fatty Liver Disease MAFLD coronary artery disease CAD is accused to be the leading cause

Patients with MAFLD are known to have more complex coronary artery disease in angiography But the effect on clinical outcome and mortality is not known Furthermore the impact of MAFLD on acute coronary syndrome ACS is not clear Moreover in patients with metabolic syndrome the presence of MAFLD would be associated with severe form of CAD as noticed by angiography where there was increased in number of affected vessels and multivariate regression analysis found that MAFLD as the only independent factor affecting coronary score

The SYNTAX score was prospectively developed for the SYNTAX trial to grade the anatomical complexity of coronary lesions in patients with lt main coronary arterty LM or three-vessel disease It was found to be an independent predictor of long-term major adverse cardiac and cerebrovascular events MACCE and of death

While the available data clearly support a role of MAFLD in initiating and progression of CAD in non-diabetic patients is still to be searched MAFLD might play a part in the pathogenesis of CAD through the overexpression and systemic release of several inflammatory hemostatic and oxidative-stress mediators or via contributing to whole-body insulin resistance and atherogenic dyslipidemia

Based on the lack of studies that discussed the effect of MAFLD on patients with ACS we designed this study trying to asses the effect of MAFLD on the severity of ACS

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None